Welcome to our dedicated page for Sellas Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on Sellas Life Sciences Group stock.
SELLAS Life Sciences Group Inc (SLS) is a clinical-stage biopharmaceutical company advancing novel therapies through strategic oncology research and development. This news hub provides investors and medical professionals with timely updates on clinical trial progress, regulatory milestones, and therapeutic innovations.
Access consolidated information about the company’s lead candidates: galinpepimut-S (GPS) for WT1-expressing cancers, and SLS009, a CDK9 inhibitor targeting hematologic malignancies. Stay informed about Phase 3 trial developments, partnership announcements, and scientific presentations.
Key updates include treatment efficacy data, trial design modifications, regulatory designations (Orphan Drug/Rare Pediatric Disease), and biomarker research advancements. All content undergoes rigorous verification to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to SELLAS’ latest developments in precision oncology. Combine our updates with SEC filings and peer-reviewed publications for comprehensive analysis of the company’s therapeutic pipeline and market position.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced the acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The poster will detail a study on the efficacy and safety of galinpepimut-S (GPS) maintenance therapy for patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line therapy. The study, led by Dr. Omer Jamy, Principal Investigator, will be presented on June 5, 2023. Additionally, SELLAS is advancing its cancer therapies, notably GPS, targeting the WT1 protein across various malignancies, and GFH009, a CDK9 inhibitor licensed from GenFleet Therapeutics.
FAQ
What is the current stock price of Sellas Life Sciences Group (SLS)?
What is the market cap of Sellas Life Sciences Group (SLS)?
